Provigil (Modafinil) Dosing in Renal Impairment: Evidence-Based Adjustments

Modafinil (brand name Provigil) is a wakefulness-promoting agent approved by the FDA for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. It is a schedule IV controlled substance available only by prescription. This article is about a narrower question than "does modafinil need a kidney dose adjustment" in the abstract: it is about which specific level of kidney function actually changes what a clinician should prescribe, and where the evidence runs out.

The direct answer and its boundary

Modafinil itself is metabolized mainly in the liver, but a large share of the resulting metabolites is cleared by the kidneys. The FDA label for Provigil calls for dose reduction specifically in severe chronic renal failure; it does not specify an exact replacement dose or provide separate instructions for mild or moderate impairment. In practice, clinicians commonly reduce the standard 200 mg daily dose to 100 mg daily when kidney function is severely reduced, then adjust based on response and tolerability, because there is no dedicated dose-finding trial in this population to justify a more granular schedule. This is the single fact-dense claim worth quoting on its own, and it should be read with that scope attached: it applies to severe renal impairment specifically, not to CKD in general, and it reflects label guidance plus common clinical extrapolation rather than a trial-tested titration schedule.

Why kidney function is relevant to a hepatically metabolized drug

Modafinil promotes wakefulness through a mechanism that differs from classic stimulants. It is understood to increase extracellular dopamine by inhibiting the dopamine transporter, and it also engages orexin, histaminergic, and noradrenergic wakefulness circuits. A substantial share of an oral dose is metabolized in the liver, chiefly through amide hydrolysis to modafinil acid, with a smaller contribution from CYP3A4-mediated oxidation to modafinil sulfone. Neither metabolite is considered pharmacologically active at the receptors responsible for the wakefulness effect. However, most of the dose, largely as these metabolites rather than unchanged drug, leaves the body through the kidneys. When glomerular filtration falls, metabolite clearance falls with it, and concentrations rise. That is the mechanistic basis for the renal dosing caution, independent of any single precise fold-change number.

A broader review of modafinil's approved and investigational uses, including its pharmacology and populations studied, is available in the peer-reviewed literature and is a reasonable starting point for readers who want background beyond the label itself (Approved and investigational uses of modafinil: an evidence-based review, 2008). That review predates the most recent label revisions, so it should be read as background context rather than as current dosing guidance.

What the FDA label actually specifies

The Provigil prescribing information addresses renal impairment briefly: it directs that the dose be reduced in patients with severe chronic renal failure, generally referenced as a creatinine clearance at or below 20 mL/min. It does not name a specific milligram target, does not provide a titration table, and does not address mild-to-moderate impairment (roughly CKD stages 1 through 3) as a distinct category at all. Readers and prescribers should treat the absence of guidance for milder impairment as a gap in the available data, not as reassurance that the drug is fully characterized in that population. Because label language and formatting can change between revisions, anyone relying on the exact wording or numeric threshold should confirm the current label text directly at the FDA's site rather than from a secondary summary, including this one.

Evidence boundary: what is established, what is plausible, what is not known

Established: Modafinil undergoes primarily hepatic metabolism, with the majority of the administered dose eliminated in urine as metabolites rather than parent drug. The FDA label instructs dose reduction in severe renal failure.

Plausible but not rigorously quantified in trials: That metabolite accumulation in severe renal impairment meaningfully raises the risk of side effects such as headache, insomnia, or anxiety through protein-binding displacement of the parent drug. This is a reasonable pharmacologic hypothesis, but a dedicated study measuring free-drug fraction at steady state in CKD patients does not appear to exist in the readily available literature, and any specific fold-change figure for metabolite accumulation should be checked against the primary pharmacokinetic paper before being treated as authoritative.

Not established: A validated dosing schedule for CKD stages 1 through 4, a measured hemodialysis extraction ratio for modafinil, dosing in continuous renal replacement therapy, and a controlled efficacy and safety trial of modafinil for dialysis-related fatigue large enough to support routine use. Claims implying precision in any of these areas (specific percentages, specific patient counts, specific improvement percentages from small pilot studies) should be treated as unverified until confirmed against the original paper, and this draft intentionally avoids presenting such numbers as settled.

A decision framework for modafinil dosing across kidney function

This framework is organized around the decision a prescriber actually has to make at each visit, not around a restatement of CKD staging definitions.

The exception that matters most for safety is the transplant patient. Modafinil is a CYP3A4 inducer at higher doses, and the FDA label warns that it can reduce blood concentrations of cyclosporine. In a kidney transplant recipient, that interaction is a rejection risk, not a dosing footnote, and it should generally take priority over the renal-clearance question when deciding whether to prescribe modafinil at all.

Interactions that compound renal risk

A few interactions are worth flagging specifically for CKD patients, because this population is more likely to be on the interacting drug and less able to tolerate the consequence.

Cyclosporine and tacrolimus. Modafinil's CYP3A4 induction can lower cyclosporine levels; the FDA label states this explicitly. Tacrolimus, also a CYP3A4 substrate, carries a plausible but less well-characterized version of the same risk. Frequent trough monitoring is warranted if the combination cannot be avoided.

Warfarin. Modafinil inhibits CYP2C19, which can affect S-warfarin metabolism and INR. Closer INR monitoring is reasonable when starting modafinil in a warfarin-treated patient, particularly one with CKD who already has elevated bleeding risk.

Phenytoin. As a CYP2C19 substrate, phenytoin levels may rise with concurrent modafinil use; monitoring is warranted where phenytoin is used for neuropathic symptoms in CKD.

NSAIDs. Modafinil has a mild pressor effect. Combined with regular NSAID use in a patient with reduced renal reserve, the hemodynamic burden may be additive, which is a reason for added caution rather than an absolute contraindication.

Dialysis and continuous renal replacement therapy

Modafinil is moderately protein-bound, which makes efficient removal by conventional intermittent hemodialysis unlikely on pharmacologic grounds. No published study appears to have directly measured its extraction ratio across a dialysis membrane, so this remains an inference from protein binding and volume of distribution rather than a measured fact. Peritoneal dialysis clears solutes more slowly than hemodialysis, so metabolite accumulation could plausibly be greater in that group, though data are limited. Continuous renal replacement therapy in an ICU setting is a distinct scenario with more sustained solute clearance; no dedicated pharmacokinetic study of modafinil in CRRT appears to be available, so dosing in that setting should be treated as off-label extrapolation with close monitoring rather than an established protocol.

Off-label use for CKD-related fatigue

Fatigue is common among patients on dialysis, and its causes are usually multifactorial, including anemia, uremic toxin burden, sleep fragmentation, and depression. Small pilot studies have examined modafinil for fatigue in dialysis populations. These studies are limited by small sample sizes and short duration, and the specific effect sizes reported in secondary summaries should be verified against the original trial report before being cited as evidence of efficacy. The reasonable clinical takeaway is that modafinil is not an established treatment for CKD-related fatigue, that anemia correction and sleep-disorder treatment should be addressed first, and that a time-limited trial at a reduced starting dose is a judgment call some clinicians make in refractory cases rather than a guideline-endorsed therapy.

When modafinil is best avoided regardless of renal dose adjustment

• Uncontrolled hypertension, since modafinil has a mild pressor effect that adds risk on top of an already difficult-to-control blood pressure.
• A history of serious hypersensitivity reactions, including severe skin reactions, which the FDA label identifies as a rare but serious risk.
• Concurrent high-dose cyclosporine or tacrolimus therapy where trough-level monitoring cannot be done frequently, given the CYP3A4 induction risk to transplant immunosuppression.
• Combined severe hepatic and severe renal impairment, where the label's separate hepatic dose-reduction advice and the renal dose-reduction advice have not been studied together, and stacking two reductions is not a validated approach.

When urgent evaluation is appropriate

New or worsening chest pain, palpitations, signs of a severe skin reaction (blistering, mucosal involvement, fever with rash), signs of an allergic reaction, or a significant, sustained rise in blood pressure after starting modafinil warrant prompt medical evaluation rather than waiting for a scheduled follow-up.

A note on individualized dosing

Nothing in this article should be used to select a specific dose for a specific patient. Renal function, hepatic function, concurrent medications, dialysis modality, and the underlying indication for modafinil all interact, and the published evidence base for dosing in kidney disease is thin enough that individualized decisions belong with the prescribing clinician, informed by current labeling and, where available, a clinical pharmacist familiar with renal drug dosing.